Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-26M | $-26M | $-12M | 154.2% | - | 91.4% |
| 2024 | $0M | $-13M | $-14M | $-12M | 88.7% | - | -77.3% |
| 2023 | $0M | $-59M | $-60M | $-8M | 64.0% | - | -1471.9% |
| 2022 | $0M | $4M | $4M | $-0M | 1.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 0.95 | 8.84 | 53.56 | 26.14 |
| Research And Development | - | 5.77 | 4.40 | 31.03 | 11.11 |
| Selling General And Administration | - | 0.95 | 4.44 | 22.53 | 15.03 |
| Total Expenses | - | 0.95 | 8.84 | 53.56 | 26.14 |
| Operating Income | - | -0.95 | -8.84 | -53.56 | -26.14 |
| Total Operating Income As Reported | - | -13.72 | -8.84 | -53.56 | -26.14 |
| EBITDA | - | 4.41 | -58.89 | -13.14 | -25.57 |
| Normalized EBITDA | - | -0.95 | -58.89 | -4.69 | -25.63 |
| EBIT | - | 4.41 | -59.27 | -13.54 | -26.08 |
| Interest Expense | - | 0 | 1.21 | 0.18 | 0.20 |
| Net Interest Income | - | 0 | -1.21 | -0.18 | -0.20 |
| Other Non Operating Income Expenses | -10.38 | -7.38 | -50.43 | 48.47 | - |
| Other Income Expense | - | 5.36 | -50.43 | 40.02 | 0.06 |
| Interest Expense Non Operating | - | 0 | 1.21 | 0.18 | 0.20 |
| Net Non Operating Interest Income Expense | - | 0 | -1.21 | -0.18 | -0.20 |
| Pretax Income | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 1.13 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income From Continuing And Discontinued Operation | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income From Continuing Operation Net Minority Interest | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Common Stockholders | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Including Noncontrolling Interests | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Normalized Income | - | 0.17 | -60.48 | -5.28 | -26.34 |
| Diluted NI Availto Com Stockholders | - | 4.41 | -60.48 | -13.73 | -26.28 |
| Basic Average Shares | - | 2.40 | 3.31 | 2.93 | 3.32 |
| Diluted Average Shares | - | 2.40 | 3.31 | 2.93 | 3.32 |
| Reconciled Depreciation | - | 0.23 | 0.38 | 0.40 | 0.51 |
| Total Unusual Items | - | 5.36 | 0 | -8.45 | 0.06 |
| Total Unusual Items Excluding Goodwill | - | 5.36 | 0 | -8.45 | 0.06 |
| Special Income Charges | - | 0 | 0 | -7.50 | 0 |
| Write Off | - | 0 | 0.25 | - | - |
| Restructuring And Mergern Acquisition | - | - | 0 | 7.50 | 0 |
| Gain On Sale Of Security | - | 5.36 | 2.71 | -0.95 | 0.06 |
| General And Administrative Expense | - | 0.95 | 4.44 | 22.53 | 15.03 |
| Other Gand A | - | 0.95 | 3.34 | 7.05 | 4.15 |
| Salaries And Wages | - | 5.80 | 1.10 | 15.48 | 10.88 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tevogen Bio Holdings Inc.this co. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| DocGo Inc. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% | -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M |
| - |
| - |
| - |
| - |
| -2.09 |
| 5.86 |
| -280.5% |
| - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| Peer Median | - | -1.18 | 1.06 | -118.2% | -0.47 | |
Historically, Oct has averaged the highest return (+142.1%); Mar the lowest (-26.4%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.2%Negative MonthJan 2026: -8.16% | -13.2%Negative MonthFeb 2026: -13.16% | -65.8%Negative MonthMar 2026: -65.76% | +46.9%Positive MonthApr 2026: +46.90% | +19.1%Positive MonthMay 2026: +19.13% | -28.4%Negative MonthJun 2026: -28.45% | +24.6%Positive MonthJul 2026: +24.56% | -8.9%*Negative MonthAug 2026: -8.94% | — | — | — | — |
| 2025 | +44.7%Positive MonthJan 2025: +44.66% | -14.1%Negative MonthFeb 2025: -14.09% | -15.6%Negative MonthMar 2025: -15.63% | -4.6%Negative MonthApr 2025: -4.63% | +25.2%Positive MonthMay 2025: +25.24% | -3.1%Negative MonthJun 2025: -3.10% | -20.9%Negative MonthJul 2025: -20.88% | -8.0%Negative MonthAug 2025: -7.99% | -13.7%Negative MonthSep 2025: -13.74% | -20.0%Negative MonthOct 2025: -20.00% | -29.8%Negative MonthNov 2025: -29.78% | -24.9%Negative MonthDec 2025: -24.94% |
| 2024 | -52.7%Negative MonthJan 2024: -52.65% | +47.4%Positive MonthFeb 2024: +47.44% | -51.7%Negative MonthMar 2024: -51.74% | -73.3%Negative MonthApr 2024: -73.33% | -19.2%Negative MonthMay 2024: -19.20% | -10.5%Negative MonthJun 2024: -10.52% | -11.5%Negative MonthJul 2024: -11.48% | -18.4%Negative MonthAug 2024: -18.44% | -29.5%Negative MonthSep 2024: -29.50% | +587.5%Positive MonthOct 2024: +587.50% | -48.2%Negative MonthNov 2024: -48.22% | -21.4%Negative MonthDec 2024: -21.37% |
| 2023 | +0.0%Neutral MonthJan 2023: +0.00% | +4.1%Positive MonthFeb 2023: +4.07% | +0.3%Neutral MonthMar 2023: +0.33% | +2.0%Neutral MonthApr 2023: +1.99% | -2.3%Negative MonthMay 2023: -2.27% | -0.7%Neutral MonthJun 2023: -0.65% | +0.3%Neutral MonthJul 2023: +0.28% | +0.6%Neutral MonthAug 2023: +0.56% | +0.6%Neutral MonthSep 2023: +0.56% | +0.4%Neutral MonthOct 2023: +0.37% | +1.6%Neutral MonthNov 2023: +1.56% | +0.8%Neutral MonthDec 2023: +0.82% |
| 2022 | — | +0.1%Neutral MonthFeb 2022: +0.10% | +0.6%Neutral MonthMar 2022: +0.60% | +0.3%Neutral MonthApr 2022: +0.30% | -0.3%Neutral MonthMay 2022: -0.30% | +0.2%Neutral MonthJun 2022: +0.20% | +0.6%Neutral MonthJul 2022: +0.65% | +0.2%Neutral MonthAug 2022: +0.25% | +0.4%Neutral MonthSep 2022: +0.45% | +0.4%Neutral MonthOct 2022: +0.44% | +0.6%Neutral MonthNov 2022: +0.59% | +0.8%Neutral MonthDec 2022: +0.78% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 5 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
